Dr. Albala on the recent CMS change for Rezum water vapor therapy


“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.

In this video, David M. Albala, MD, discusses the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy. This new change allows for more financial coverage for patients with benign prostatic hyperplasia (BPH) who seek this treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.

Related Videos
Roger R. Dmochowski, MD, MMHC, FACS, answers a question during a Zoom video interview
Smita De, MD, PhD, answers a question during a Zoom video interview
© 2023 MJH Life Sciences

All rights reserved.